Findings

What do systematic reviews say?

70 questions · 78 findings · 8 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 14 · 17.9%GRADE not reported 3 · 3.8%Very low 6 · 7.7%Low 37 · 47.4%Moderate 16 · 20.5%High 2 · 2.6%

Tacrolimus 0.1% vs mometasone furoate ointment

Primary outcome 3: Adverse events · people with moderate to severe chronic relapsing dyshidrotic eczema on hands

1 finding from 1 review

Interventions for hand eczema 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 16 participants
Moderate

Tacrolimus 0.1% vs mometasone furoate ointment

Secondary: investigator‐rated reduction in severity ‐ DASIb · people with moderate to severe chronic relapsing dyshidrotic eczema on hands

1 finding from 1 review

Interventions for hand eczema 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 16 participants
Moderate

Tacrolimus 0.1% vs vehicle

Primary: investigator‐rated good/excellent control of symptoms · people with moderate to severe nickel sulphate‐induced allergic contact dermatitis based on clinical history (hand eczema) and proven by…

Topical calcineurin inhibitors: tacrolimus 0.1% ointment probably leads to higher primary: investigator‐rated good/excellent control of symptoms compared with vehicle (moderate certainty).

1 finding from 1 review

Interventions for hand eczema 2019 · Cochrane Headline outcomes only
RR 29 [1.9, 443.25]
1 study · 28 participants
Moderate

Tacrolimus 0.1% vs vehicle

Primary: participant‐rated good/excellent control of symptoms Not measured · people with moderate to severe nickel sulphate‐induced allergic contact dermatitis based on clinical history (hand eczema) and proven by…

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for hand eczema 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Tacrolimus 0.1% vs vehicle

Primary: adverse events ‐ burning/itching at application site · people with moderate to severe nickel sulphate‐induced allergic contact dermatitis based on clinical history (hand eczema) and proven by…

Topical calcineurin inhibitors: tacrolimus 0.1% ointment showed no clear difference in primary: adverse events ‐ burning/itching at application site compared with vehicle (moderate certainty).

1 finding from 1 review

Interventions for hand eczema 2019 · Cochrane Headline outcomes only
RR 9 [0.53, 152.93]
1 study · 28 participants
Moderate

Tacrolimus 0.1% vs vehicle

Secondary: investigator‐rated reduction in severity ‐ Not measured · people with moderate to severe nickel sulphate‐induced allergic contact dermatitis based on clinical history (hand eczema) and proven by…

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for hand eczema 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Any topical or systemic intervention (topical/systemic steroids, ciclosporin, tacrolimus, retinoids, anti-malarials, biologics, phototherapy, surgery) vs Placebo, no treatment, another active intervention, or a different dose of the same intervention

Eating a normally varied diet · People of any age with erosive lichen planus affecting the oral, anogenital, and/or oesophageal regions

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for erosive lichen planus affecting mucosal sites 2012 · Cochrane All outcomes
No studies reported this outcome.
0 studies
No studies found

Any topical or systemic intervention (topical/systemic steroids, ciclosporin, tacrolimus, retinoids, anti-malarials, biologics, phototherapy, surgery) vs Placebo, no treatment, another active intervention, or a different dose of the same intervention

Restoration of sexual activity · People of any age with erosive lichen planus affecting the oral, anogenital, and/or oesophageal regions

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for erosive lichen planus affecting mucosal sites 2012 · Cochrane All outcomes
None of the included studies assessed the effectiveness of treatments of genital ELP; thus, this outcome was not reported.
0 studies
No studies found

Any topical or systemic intervention (topical/systemic steroids, ciclosporin, tacrolimus, retinoids, anti-malarials, biologics, phototherapy, surgery) vs Placebo, no treatment, another active intervention, or a different dose of the same intervention

Reduction in number of flares · People of any age with erosive lichen planus affecting the oral, anogenital, and/or oesophageal regions

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for erosive lichen planus affecting mucosal sites 2012 · Cochrane All outcomes
No studies reported this outcome.
0 studies
No studies found

Any topical or systemic intervention (topical/systemic steroids, ciclosporin, tacrolimus, retinoids, anti-malarials, biologics, phototherapy, surgery) vs Placebo, no treatment, another active intervention, or a different dose of the same intervention

Reduction in severity of flares · People of any age with erosive lichen planus affecting the oral, anogenital, and/or oesophageal regions

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for erosive lichen planus affecting mucosal sites 2012 · Cochrane All outcomes
No studies reported this outcome.
0 studies
No studies found